Glaukos Announces Participation in the Stephens Annual Investment Conference

Rhea-AI Summary

Glaukos Corporation (NYSE: GKOS) announced management's participation in the Stephens Annual Investment Conference on November 16, 2022, at 2:00 p.m. CT in Nashville, TN. The event will be accessible via a live and archived webcast on their Investors section of the website. Glaukos specializes in ophthalmic medical technology and pharmaceuticals, focusing on innovative treatments for glaucoma, corneal disorders, and retinal diseases. They pioneered Micro-Invasive Glaucoma Surgery (MIGS) to enhance glaucoma treatment.

Positive

• Participation in the Stephens Annual Investment Conference may enhance investor engagement.
• Glaukos continues to innovate in the ophthalmic space with a focus on glaucoma treatments.

Negative

• None.

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Stephens Annual Investment Conference on Wednesday, November 16, 2022, at 2:00 p.m. CT in Nashville, TN.

A live and archived webcast for this event will be available in the Investors section of the Glaukos website at http://investors.glaukos.com.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012, and continues to develop a portfolio of technologically distinct and leverageable platforms to support ongoing pharmaceutical and medical device innovations. Products or product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of glaucoma, corneal disorders and retinal diseases.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221107005122/en/

Chris Lewis

Vice President, Investor Relations & Corporate Affairs

(949) 481-0510

clewis@glaukos.com

Source: Glaukos Corporation

FAQ

When is Glaukos participating in the Stephens Annual Investment Conference?

Glaukos Corporation is participating in the Stephens Annual Investment Conference on November 16, 2022, at 2:00 p.m. CT.

Where is the Stephens Annual Investment Conference being held?

The Stephens Annual Investment Conference is being held in Nashville, TN.

What is Glaukos Corporation's focus in ophthalmic technology?

Glaukos Corporation focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.

How can I access the webcast of Glaukos' participation in the investment conference?

The live and archived webcast for Glaukos' participation will be available in the Investors section of their website.